Company* (Country; Symbol) |
Company* (Country; Symbol) |
Type/Product Area |
Terms/Details (Date) |
Althea Technologies Inc.* |
GeoVax Labs Inc. (OTC BB:GOVX) |
Agreement for Althea to manufacture GeoVax's HIV-1 DNA AIDS vaccine |
The vaccine will be used in GeoVax's advanced Phase II human trials planned to start in early 2008 (6/20) |
BioMerieux SA (France; PARIS:BIM) |
AdvanDx Inc.* |
Exclusive agreement for U.S. distribution of AdvanDx's PNA FISH diagnostic tests |
The tests rapidly identify bacteria and yeast in the blood (5/23) |
CyDex Inc.* |
Critical Therapeutics Inc. (CRTX) |
License and supply agreement granting exclusive worldwide rights to CyDex's Captisol-enabling technology |
Critical Therapeutics will develop an injectable formulation of zileuton (6/12) |
Genomic Health Inc. (GHDX) |
Medical Solutions plc (UK; LSE:MLS) |
Exclusive agreement to distribute Genomic Health's Oncotype DX breast cancer assay in the UK |
Further details were not disclosed (6/1) |
Grant Life Sciences Inc. (OTC BB:GLIFE) |
Alphagenics Diaco Biotechnologies Srl* (Italy) |
Agreement under which Grant will get rights to Alphagenics' molecular diagnostic test for human papillomaviruses |
Grant will have exclusive manufacturing and marketing rights in China and the U.S., and nonexclusive rights in Europe, India, Australia and Japan (6/13) |
Laboratory Corp. of America Holdings (NYSE:LH) |
Veridex LLC* |
License agreement to commercialize nucleic acid testing technology for detecting the presence of a tissue marker in prostate cancer, methylated GST-Pi |
LabCorp said it was the first full-service national clinical laboratory in the U.S. to license the technology; terms were not disclosed (5/29) |
OncoMethylome Sciences SA (Belgium; BR:ONCOB) |
Exact Sciences Corp. (EXAS) |
Agreements to advance the commercialization of stool-based colorectal cancer screening technologies through laboratories in Europe and North America |
Exact granted nonexclusive rights to its DNA stabilization, isolation and extraction technology; OncoMethylome agreed to pay royalties on sales (6/12) |
ProNAi Therapeutics Inc.* |
Polymun Scientific GmbH* (Austria) |
Agreement to manufacture ProNAi's PNT2258 DNAi- based cancer therapeutic |
Polymun will use its cross-flow injector technology to manufacture ProNAi's liposome-formulated lead drug candidate (6/14) |
Qiagen NV (QGEN) systems |
Biomatrica Inc.* |
License and marketing agreement for the exclusive distribution of room temperature DNA storage technology for biological sample storage and sample management |
Biomatrica's SampleMatrix technology and Qiagen's rights are expected to be expanded for uses including the stabilization, shipping and storage of DNA molecules in blood and buccal swab samples (5/31) |
Sloning Biotechnology* (Germany) |
Microsynth AG* (Switzerland) |
Distribution partnership for Microsynth to exclusively market and sell Sloning's gene synthesis service, Slonomics, in Switzerland |
It also will sell the product family of mutant libraries, Slonomax (6/1) |
| | |||
Notes: | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
BR = Brussels Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board. | |||
